VENLABIC XR venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

venlafaxine hydrochloride, Quantity: 42.45 mg (Equivalent: venlafaxine, Qty 37.5 mg)

Available from:

GM Pharma International Pty Ltd

INN (International Name):

Venlafaxine hydrochloride

Pharmaceutical form:

Capsule, modified release

Composition:

Excipient Ingredients: microcrystalline cellulose; copovidone; Gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; Shellac; ethanol absolute; ammonia

Administration route:

Oral

Units in package:

28 capsules

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

VENLABIC XR is indicated for the treatment of: - Major depression, including prevention of relapse and recurrence where appropriate; - Generalised anxiety disorder; - Social anxiety disorder; Panic disorder, including prevention of relapse.

Product summary:

Visual Identification: Light grey opaque cap/peach opaque body, size '3' hard capsule with thick and thin radial circular bands on both the cap and body in red ink.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Licence status A

Authorization date:

2017-05-17